Tetraphase On Track For Antibiotic Submission In 2015
This article was originally published in The Pink Sheet Daily
The biotech reported positive topline data from an interim analysis of its second Phase III trial that puts it on track to release data, submit and potentially see approval next year.
You may also be interested in...
A pair of biotech IPOs priced on March 20 with mixed results. Hepatitis C developer Enanta got a warm reception from investors looking to tap into what has been a lucrative sector. But antibiotics company Tetraphase priced below its range and traded flat.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.